Editor's note
Welcome to The CareCore Stack.
This is for people building longevity medicine under real constraints: clinical, regulatory, pharmacy, product, data, and incentives.
Issue 001 starts with a weirdly exciting market moment: peptides are moving from forum lore and clinic menus into the regulatory machinery of care.
The question is no longer just “which peptides come back?” It is whether access can become accountable care.
The take
The short version
- FDA has opened a Pharmacy Compounding Advisory Committee process and public docket. It has not restored blanket peptide access.
- Demand did not wait for regulatory clarity. After the 2023 Category 2 restrictions, research-use and gray-market channels became harder to ignore.
- “Peptide therapy” collapses different businesses: FDA-approved drugs, compounding candidates, topical products, and research or influencer stacks.
- If access expands, the edge is not menu size. It is molecule-level governance: legal pathway, pharmacy quality, eligibility, consent, monitoring, adverse-event workflow, and stop rules.
Peptides are being covered like a reopening story.
That is premature, and a little too small.
FDA scheduled a Pharmacy Compounding Advisory Committee meeting for July 23 to 24, 2026. The committee's review set included selected peptide-related bulk drug substances for possible inclusion on the Section 503A Bulks List.
| Timing | Peptide-related substances |
|---|---|
| July 23 to 24, 2026 PCAC | BPC-157-related substances, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, Epitalon |
| Expected later PCAC before the end of February 2027 | LL-37, GHK-Cu, Dihexa acetate, Melanotan II, PEG-MGF |
That is not a launch date. It is a regulatory process. FDA opened a docket. The committee will advise. FDA still has to decide what happens next.
The more interesting market read is that demand is already here. If access becomes predictable, access will commoditize. The moat shifts to the care model around the molecule.
The backstory
Peptides are not new to medicine. Insulin is a peptide hormone. GLP-1 drugs made peptide therapeutics mainstream.
Compounding pharmacies have long filled narrower needs when a patient requires a form, dose, or formulation that a manufacturer does not sell. The longevity industry changed the packaging.
Peptides became a consumer category: recovery, fat loss, sleep, skin, libido, injury, immunity, anti-aging. Some of that interest is biologically plausible. Some of it is extrapolation wearing a white coat. The label worked because it mapped onto how biohackers already buy optimization: add a layer, tune the inputs, recover faster, sleep deeper, heal faster, age better.
Then access narrowed.
In 2023, FDA placed multiple peptide bulk drug substances into Category 2, the bucket for nominated substances where FDA had identified potential significant safety risks in compounding pending further evaluation.
Licensed pharmacy access narrowed. Demand did not disappear. A user could read Reddit, compare vendor spreadsheets, buy a vial, order syringes, and arrive at a visit already fluent in mechanism, dose lore, and forum anecdotes. Not necessarily correct. But certainly confident.
The operator lesson: research use only shifts liability. A certificate of analysis may answer identity or purity. It does not create prescription oversight, sterility assurance, adverse-event capture, or recall accountability. A vial can contain the right molecule and still be the wrong thing to inject.
For the consumer and harm-reduction background, see my gray-market peptide guide.
Where that puts us today
This is the market any legitimate reopening lands in: high demand, consumer fluency, weak trust, and buyers who conflate certificates of analysis, pharmacy compounding, FDA approval, sterility, and clinical oversight.
The core category error is simple. These are not the same business:
| Lane | Examples | Operator problem |
|---|---|---|
| FDA-approved peptide drugs | GLP-1s, bremelanotide, tesamorelin | Label logic, off-label use, contraindications, monitoring, payer constraints, and access. |
| Formerly FDA-approved or compounded today | Sermorelin acetate (Geref) | Current clinical use still needs its own indication, source, consent, and monitoring file. |
| Established elsewhere or off-label | Thymosin alpha-1, Selank | U.S. status, sourcing, claims, and patient counseling need their own file. |
| 503A or PCAC review set | BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax, Epitalon, and the later review set | PCAC review is not authorization. Use case, route, form, and evidence tier matter. |
| Topical or cosmetic peptides | Topical GHK-Cu, cosmetic signal peptides | Topical evidence does not transfer cleanly to injectable use or systemic claims. |
| Research or influencer stacks | Multi-vial recovery protocols, RUO products | No prescription, pharmacy accountability, adverse-event capture, or defensible patient selection. |
A peptide program has to answer boring questions before it earns the right to be interesting. What exact molecule, salt, analog, or fragment is this? What is the proposed use? What human evidence supports that use? What legal pathway supports access today? Which route is being used? Which pharmacy prepares it? Who qualifies? Who is excluded? What gets monitored? What makes us stop?
The meaning
FDA opened a planning window, not a free-for-all.
FDA docket FDA-2025-N-6895 set a July 23 to 24, 2026 PCAC meeting. The docket closed July 22, and comments submitted by July 9 were intended for committee review.
Operator read: This is the moment to build the file, not the landing page.
The proposed uses are the tell.
The July agenda was not a generic longevity menu. Proposed uses spanned ulcerative colitis, wound healing, inflammatory conditions, obesity, osteoporosis, opioid withdrawal, insomnia, narcolepsy, cerebral ischemia, and trigeminal neuralgia.
Operator read: Claims architecture matters. The molecule, route, use case, and evidence tier have to match.
The GLP-1 halo is doing too much work.
GLP-1s taught the public that a peptide can change physiology at scale. That credibility now spills onto molecules with far thinner human evidence.
Operator read: Serious products separate validated peptide drugs, compounding candidates, cosmetic or topical peptides, and RUO stacks instead of selling one blended promise.
The gray-market customer is already trained.
Consumers learned to compare certificates of analysis, vendor spreadsheets, Reddit dosing lore, and recovery, fat-loss, or sleep stacks before many clinics had a serious governance model.
Operator read: Demand is not the scarce asset. Trust, documentation, monitoring, and the ability to say no are.
Compounding quality is product architecture.
FDA notes that compounded drugs are not FDA-approved, and that bulk drug substances used in 503A or 503B compounding require documentation such as a valid certificate of analysis and an FDA-registered manufacturer.
Operator read: Source quality, pharmacy pathway, lot control, and recall workflow belong in the product specification.
The build
The stack decoder
A lot of peptide confusion comes from collapsing the supply chain.
| Term | Plain-English version | Why it matters |
|---|---|---|
| Active pharmaceutical ingredient or bulk drug substance | The active ingredient before it becomes a finished drug. | The question is whether the source is legal, documented, and suitable for patient use. |
| 503A pharmacy | A state-licensed pharmacy compounding for an individual patient prescription. | It can solve patient-specific needs, but compounded drugs are not FDA-approved finished products. |
| 503B outsourcing facility | An FDA-registered outsourcing facility subject to current good manufacturing practice requirements. | It still operates under compounding rules, not the same path as a new FDA-approved drug. |
| Manufacturer | A company making an FDA-approved finished drug product. | This is not the same thing as a pharmacy preparing a patient-specific compounded medication. |
| Research use only or gray-market seller | A vendor selling research-use or non-prescription material outside a clinical pharmacy relationship. | A certificate of analysis does not create prescription oversight, sterility assurance, adverse-event capture, or recall accountability. |
Not all overseas active pharmaceutical ingredient manufacturing is suspect. Big pharma, generic manufacturers, and legitimate compounders all depend on global ingredient supply chains.
The difference is the paper trail: registered establishment, valid certificate of analysis, legal eligibility, pharmacy accountability, testing, lot control, and a recall path.
In product terms, those are separate objects: molecule, source, pharmacy pathway, patient eligibility, monitoring, and recall workflow. Miss one layer and the risk flows downstream.
The template
Peptide governance checklist
Copy this into the roadmap before adding a peptide to a clinical product, provider workflow, marketplace, or creator-led health program. Every line should have an owner, artifact, and stop rule.
- Molecule identity: Exact molecule, salt, analog, fragment, dose form, and route are named.
- Use case: The specific indication or goal is defined. No vague longevity promise.
- Evidence: Human evidence, animal data, mechanism, topical evidence, and anecdote are separated.
- Legal pathway: Current FDA, 503A, 503B, and state status are documented for this exact use and formulation.
- Source quality: Pharmacy, API source, certificate of analysis, sterility, endotoxin, lot, cold-chain, and recall records are retrievable.
- Patient selection: Inclusion criteria, exclusions, baseline data, interactions, and clinician authority are defined.
- Consent: Consent language distinguishes approval, uncertainty, route risk, and evidence limits.
- Monitoring: Follow-up timing, outcomes, adverse events, escalation, and discontinuation rules are defined.
- Stop rule: Clinicians can say no, pause, or discontinue when demand is stronger than the case.
A missing check is not a green light. It is a scope boundary: do not offer it, pilot only, or build the missing layer before scale.
The takeaway
This is why I find peptides exciting: they sit where biology, demand, regulation, and product design collide.
A molecule can be promising and still be the wrong thing to sell casually.
Forward this to the person about to add “peptides” to a roadmap.
Then ask one question:
The market is already moving. The care model has to catch up.
To your success,
Hillary Lin, MD
Primary references